[HIV-associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[HIV-associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?]

Dtsch Med Wochenschr. 1996 Jan 26;121(4):83-9. Unique Identifier : AIDSLINE MED/96223711
Ewig S; Rockstroh JK; Schafer H; Leutner C; Pickenhain A; Luderitz B; Medizinische Universitatsklinik und Poliklinik sowie; Radiologische Universitatsklinik Bonn.


Abstract: OBJECTIVE: To study the effect of pentamidine aerosol inhalation, known to be effective and well tolerated in the primary prevention of HIV-associated Pneumocystis carinii pneumonia (PCP), on the severity, on clinical and radiological findings and prognosis of break-through PCP. PATIENTS AND METHODS: Data were obtained from the case notes of 17 men (mean age 36 [23-55] years) with HIV-associated PCP, treated between 1989 and 1994, who had received primary prophylaxis with pentamidine aerosol. During the same period 42 patients with HIV-associated PCP but no pentamidine prophylaxis (39 men, three women; mean age 36 [21-67] years) were also treated. Bronchoalveolar lavage of the most affected segment was performed. Diagnostic measures and treatment remained constant during the period of observation. RESULTS: The clinical presentation was the same in the two groups. There was also no difference between them regarding sensitivity to the lavage (94 and 98%). However, infiltration of the upper segments was significantly more common in the prophylaxis group (90 and 43%; P < 0.02). There was no statistically significant difference between the two groups in death rate (13 and 7%) and the long-term prognosis after PCP (survival time 18 and 24 months, respectively). CONCLUSION: Primary prophylaxis of PCP had no significant effect other than altering the distribution pattern of the pneumonic infiltrates towards the apical segments.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Aerosols Aged Antifungal Agents/*ADMINISTRATION & DOSAGE Comparative Study English Abstract Female Human Male Middle Age Pentamidine/*ADMINISTRATION & DOSAGE Pneumonia, Pneumocystis carinii/DIAGNOSIS/MORTALITY/*PREVENTION & CONTROL Respiratory Therapy Time Factors Tomography, X-Ray Computed JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDcomplicationsadultaerosolsagedantifungalagents/KWDadministration&dosagecomparativestudyenglishabstractfemalehumanmalemiddleagepentamidine/KWDadministration&dosagepneumonia,pneumocystiscarinii/diagnosis/mortality/KWDprevention&controlrespiratorytherapytimefactorstomography,x-raycomputedjournalarticle
960930
M9690919

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .